>
Benitec Biopharma Inc logo

BNTC - Benitec Biopharma Inc Share Price

$4.97 0.1  1.0%

Last Trade - 09/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £82.3k
Enterprise Value £-10.1m
Revenue £121k
Position in Universe 6772nd / 6827
Bullish
Bearish
Unlock BNTC Revenue
Momentum
Relative Strength (%)
1m +49.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -71.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
2.83 2.95 8.36 3.58 11.9 0.10 0.11 -48.5%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, BenitecBiopharma Inc revenues totaled $56K. Net loss totaled to$6M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BNTC Revenue Unlock BNTC Revenue

Net Income

BNTC Net Income Unlock BNTC Revenue

Normalised EPS

BNTC Normalised EPS Unlock BNTC Revenue

PE Ratio Range

BNTC PE Ratio Range Unlock BNTC Revenue

Dividend Yield Range

BNTC Dividend Yield Range Unlock BNTC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BNTC EPS Forecasts Unlock BNTC Revenue
Profile Summary

Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
No. of Shareholders: n/a
No. of Employees: 13
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 22,702
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BNTC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BNTC
Upcoming Events for BNTC
Frequently Asked Questions for Benitec Biopharma Inc
What is the Benitec Biopharma Inc share price?

As of 09/04/21, shares in Benitec Biopharma Inc are trading at $4.97, giving the company a market capitalisation of £82.3k. This share price information is delayed by 15 minutes.

How has the Benitec Biopharma Inc share price performed this year?

Shares in Benitec Biopharma Inc are currently trading at $4.97 and the price has moved by -24.7% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Benitec Biopharma Inc price has moved by -49.24% over the past year.

What are the analyst and broker recommendations for Benitec Biopharma Inc?

Of the analysts with advisory recommendations for Benitec Biopharma Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Benitec Biopharma Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Benitec Biopharma Inc next release its financial results?

Benitec Biopharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Benitec Biopharma Inc dividend yield?

Benitec Biopharma Inc does not currently pay a dividend.

Does Benitec Biopharma Inc pay a dividend?

Benitec Biopharma Inc does not currently pay a dividend.

When does Benitec Biopharma Inc next pay dividends?

Benitec Biopharma Inc does not currently pay a dividend.

How do I buy Benitec Biopharma Inc shares?

To buy shares in Benitec Biopharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Benitec Biopharma Inc?

Shares in Benitec Biopharma Inc are currently trading at $4.97, giving the company a market capitalisation of £82.3k.

Where are Benitec Biopharma Inc shares listed? Where are Benitec Biopharma Inc shares listed?

Here are the trading details for Benitec Biopharma Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BNTC
What kind of share is Benitec Biopharma Inc?

Based on an overall assessment of its quality, value and momentum, Benitec Biopharma Inc is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Benitec Biopharma Inc share price forecast 2021?

Shares in Benitec Biopharma Inc are currently priced at $4.97. At that level they are trading at 42.8% discount to the analyst consensus target price of 0.00.

Analysts covering Benitec Biopharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.3800598232 for the next financial year.

How can I tell whether the Benitec Biopharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Benitec Biopharma Inc. Over the past six months, the relative strength of its shares against the market has been 38.29%. At the current price of $4.97, shares in Benitec Biopharma Inc are trading at 3.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Benitec Biopharma Inc PE Ratio?

We were not able to find PE ratio data for Benitec Biopharma Inc.

Who are the key directors of Benitec Biopharma Inc?

We were unable to find the directors for Benitec Biopharma Inc.

Who are the major shareholders of Benitec Biopharma Inc?

Here are the top five shareholders of Benitec Biopharma Inc based on the size of their shareholding:

Nemean Asset Management, LLC Corporation
Percentage owned: 8.7% (395k shares)
Nant Capital, L.L.C. Corporation
Percentage owned: 6.45% (293k shares)
Alpha Capital Aktiengesellschaft Holding Company
Percentage owned: 5.64% (256k shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 5.49% (249k shares)
Two Sigma Investments, LP Hedge Fund
Percentage owned: 2.72% (123k shares)
Similar to BNTC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.